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AbstrAct
Small Rho GTPase (Rho) and its immediate effector Rho kinase (ROCK) are 
reported to regulate cell survival, but the detailed molecular mechanism remains 
largely unknown. We had previously shown that Rho/ROCK signaling was highly 
activated in hepatocellular carcinoma (HCC). In this study, we further demonstrated 
that downregulation of RhoE, a RhoA antagonist, and upregulation of ROCK enhanced 
resistance to chemotherapy in HCC in both in vitro cell and in vivo murine xenograft 
models, whereas a ROCK inhibitor was able to profoundly sensitize HCC tumors to 
cisplatin treatment. Specifically, the ROCK2 isoform but not ROCK1 maintained the 
chemoresistance in HCC cells. Mechanistically, we demonstrated that activation 
of ROCK2 enhanced the phosphorylation of JAK2 and STAT3 through increased 
expression of IL-6 and the IL-6 receptor complex. We also identified IKKβ as the direct 
downstream target of Rho/ROCK, and activation of ROCK2 significantly augmented 
NF-κB transcription activity and induced IL-6 expression. These data indicate that 
Rho/ROCK signaling activates a positive feedback loop of IKKβ/NF-κB/IL-6/STAT3 
which confers chemoresistance to HCC cells and is a potential molecular target for 
HCC therapy.
IntroductIon
Hepatocellular carcinoma (HCC) is the seventh 
most common cancer worldwide and ranks the third 
leading cause of cancer-related mortality [1]. HCC is 
generally resistant to systemic chemotherapy which highly 
limits treatment options to patients. On the other hand, 
sorafenib is the only molecularly targeted drug approved 
for treating patients with advanced HCC. However, 
sorafenib only extends the median overall survival of 
patients by about 3 months [2]. Cancer stem cells (CSCs), 
activation of pro-survival pathways and hypoxia are 
important molecular mechanisms contributing to the 
highly chemoresistant nature of HCC. For example, Ma et 
al has demonstrated that CD133+ HCC CSCs can activate 
Akt in order to enhance their resistance to chemotherapy 
treatment [3]. In addition, the large hypoxic core of HCC 
tumors also confers higher survival ability of HCC cells. 
Hypoxia stabilizes transcription factor HIF-1α and HIF-
1α promotes expression of pro-survival gens such as 
surviving and Bcl-2 [4] and drug-resistant genes such 
as MDR1 and P-glycoprotein [5]. Therefore there is an 
urgent need to identify new therapeutic targets to combat 
against chemoresistance in HCC and provide patients with 
more treatment choices. 
The family of small Rho GTPases is a subfamily 
of the Ras superfamily. While members of the Rho 
GTPases are most well-known for their functions in 
regulating cytoskeleton remodeling events, they are also 
reported to be involved in controlling apoptotic signaling 
and cell survival [6]. RhoA and its effector Rho kinase 
(ROCK) are reported to enhance cell survival and confer 
resistance to chemotherapy in different cancer types [7, 8]. 
However, the exact roles of Rho/ROCK in regulating HCC 
chemoresistance remain undiscovered and the detailed 
underlying mechanism remains largely unknown. 
Both JAK/STAT3 and NF-κB pathways have been 
extensively studied for their functions in promoting 
cell survival through activating transcription of many 
pro-survival genes [9, 10]. Rho/ROCK has been shown 
to interact with JAK/STAT3. Activation of RhoA can 
upregulate the phosphorylation of STAT3 at Y705 
and S727 [11] and induce activation of NF-κB [12]. 
Therefore there is a possibility that Rho/ROCK regulates 
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chemoresistance via the JAK/STAT3 and NF-κB pathways 
in HCC.
We had previously demonstrated that ROCK2 was 
overexpressed and RhoE, an antagonist of the Rho/ROCK 
signaling, was underexpressed in HCC and together 
they promote HCC metastasis [13, 14]. In this study, 
we identified that these two events resulted in hyper-
activation of ROCK2, which in turn activated an IKKβ/
NF-κB/IL-6/STAT3 positive feedback loop and conferred 
chemoresistance to HCC cells. Our work also led to the 
finding of ROCK inhibitor as a potential therapeutic agent 
for both chemo-sensitization and suppression of metastasis 
in HCC.
results
rhoe/rocK2 modulates chemoresistance in 
Hcc cells
To investigate the effect of Rho/ROCK signaling on 
chemoresistance in HCC cells, we first knocked down its 
antagonist RhoE by short-hairpin RNA (shRNA) approach 
in BEL-7402 and MHCC-97L HCC cells (Figure 1A). The 
cells were then treated with two different chemotherapeutic 
drugs, cisplatin and doxorubicin, that are used in HCC 
patients, respectively. Knockdown of RhoE repressed 
the chemodrug-induced cell death as compared with the 
non-target control (NTC) (Figure 1B). Next, we examined 
if this effect was related to ROCK activity. Addition of 
ROCK inhibitor, Y27632, to BEL-7402, MHCC-97L 
and SMMC-7721 cells significantly sensitized them 
to cisplatin treatment (Figure 1C). Moreover, the cell-
death suppression effect resulted from RhoE knockdown 
(as seen from Figure 1A) was also rescued by co-treatment 
with Y27632 for 48 hours (Figure 1D). An immortalized 
normal liver cell line LO2 was tested for the toxicity of 
combined treatment of cisplatin and Y27632. As expected, 
knockdown of RhoE by siRNA enhanced resistance 
to cisplatin in LO2 cells (Supplementary Figure 1A). 
Although co-treatment of cisplatin and Y27632 also had 
increased toxicity in LO2 cells, the degree of sensitization 
is less as compared with that in BEL-7402 and MHCC-97L 
cells (Supplementary Figure 1B). This suggests that 
Y27632 sensitizes HCC cells to cisplatin treatment more 
than normal hepatocytes. Since Rho/ROCK signaling 
was reported to regulate cell survival via modulating the 
expression of anti-apoptotic genes [7, 15], we investigated 
if cisplatin-induced apoptosis could be altered by Rho/
ROCK in BEL-7402. Annexin-V staining flow cytometry 
was performed to measure the apoptotic cell population 
induced by cisplatin treatment in RhoE-knockdown cells 
with or without the addition of Y27632 for 24 hours. 
The results demonstrated that downregulation of RhoE 
dramatically reduced the apoptotic population of cells 
(Annexin-V+ve, PI−ve) treated with cisplatin alone as 
compared with that of NTC. Reciprocally, co-treating the 
cells with Y27632 restored cisplatin-induced apoptosis 
(Figure 1E). 
ROCK has two isoforms, ROCK1 and ROCK2. 
Previous studies have suggested that these two isoforms 
have differential functions [16]. Therefore we aimed to 
find out which isoform of ROCK was responsible for 
contributing to cell survival in HCC cells. We knocked 
down ROCK1 and ROCK2 in BEL-7402 with siRNA 
and shRNA, respectively, and then treated the cells with 
cisplatin. Knockdown of ROCK1 had no observable 
effects on cisplatin-induced cell death (Figure 2A). In 
contrast, knockdown of ROCK2 significantly sensitized 
BEL-7402 to cisplatin (Figure 2B). This suggests 
that ROCK2 is able to regulate cell survival in HCC 
cells. Furthermore, since RhoE is reported to suppress 
ROCK2 activity by repressing RhoA, we knocked down 
RhoA by siRNA and found that RhoA knockdown also 
sensitized BEL-7402 cells to cisplatin (Figure 2C). Of 
note, knockdown of RhoA and ROCK2, respectively, was 
able to rescue the chemoresistance enhanced by RhoE 
knockdown (Figure 2D). 
To ensure that the effect we observed with Y27632 
was not due to non-specific activity of the inhibitor, we 
overexpressed ROCK2 in SMMC-7721 and BEL-7402 
cells using the transcription activator-like effectors 
(TALE)-linked transcription factor approach, as described 
[17] with slight modification (Supplementary Figure 2A 
and 2B). As expected, cells with ROCK2 overexpression 
showed enhanced chemoresistance and reduced apoptosis 
to cisplatin treatment as compared with the vector control 
(Supplementary Figure 2C and 2D). Taken together, 
these data strongly suggest that RhoE/ROCK2 modulates 
chemoresistance in HCC in vitro. 
rhoe/rocK2 regulates chemoresistance of 
Hcc in vivo
To investigate if the effects of RhoE/ROCK2 on 
cell survival we observed in vitro also occurred in vivo, 
we first used a subcutaneous injection model in immune-
deficient nude mice. RhoE knockdown BEL-7402 cells or 
NTC were injected subcutaneously into nude mice and the 
tumors were allowed to grow to about 100 mm3 in size. 
We then administrated the mice with either cisplatin or 
phosphate buffered saline (PBS) and the tumor growth rate 
was recorded. Tumors derived from NTC cells responded 
well to cisplatin treatment whereas tumors derived 
from RhoE knockdown cells displayed similar growth 
rates between the PBS and cisplatin treatment groups 
(Figure 3A). The same experiment was performed using 
ROCK2-overexpressing BEL7402 cells. In both ROCK2-
overexpressing clones, there was no significant difference 
between the tumor growth rates of the cisplatin- and 
PBS-treated mice. On the other hand, cisplatin treatment 
drastically inhibited tumor growth in vector control 
cells (Supplementary Figure 3A). We also tested the 
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Figure 1: rocK activity regulated chemoresistance in Hcc cells. (A) Western blot showing RhoE protein levels in both 
non-target control and shRhoE-16 infected HCC cells. (b, c and d) Quantification of percentage of cell death induced by (B) 48-hour 
treatment of cisplatin and doxorubicin in non-target control (NTC) and RhoE knockdown cells, (C) 48-hour treatment of i) mock, ii( 
cisplatin, iii) Y27632, and iv) cisplatin and Y27632. (D) 48-hour treatment of cisplatin and doxorubicin with or without Y27632 in NTC 
and RhoE knockdown cells. (e) Annexin V flow cytometry assessment of the apoptotic cell population after 24 hours of cisplatin treatment 
with or without Y27632. Cells undergoing apoptosis are represented by the Annexin V+ve/PI−ve populations (red rectangles). In all panels, 
3 experiments are represented. P-value was calculated using Student’s t test. 20 ug/ml cisplatin and 10 μM Y27632 were used.
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Figure 2: Inhibition of rocK2 but not rocK1 sensitized Hcc cells to chemotherapy. (A and b) Western blot analysis 
was used to confirm the successful knockdown of ROCK1/2 by both sh- and si-RNA. The amount of cell death 48 hours after treatment 
with cisplatin was quantified. Only knockdown of ROCK2 enhanced cisplatin-induced cell death. (c) Knockdown of the RhoA protein by 
siRNA approach was confirmed by Western blot analysis. The amount of cell death 48 hours after treatment with cisplatin was quantified. 
RhoA knockdown sensitized HCC cells to cisplatin treatment. (d) Knockdown of RhoA and ROCK2 rescued the enhanced chemoresistance 
induced by RhoE knockdown in HCC cells. In all panels, 3 experiments are represented. P-value was calculated using Student’s t test.
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chemoresistance of the NTC and RhoE knockdown HCC 
cells in an orthotopic liver injection model. MHCC-97L 
cells were used in this experiment since SMMC-7721 does 
not grow at all and BEL-7402 does not grow well in in 
the orthotopic liver injection model. Consistent with the 
results in the subcutaneous model, cisplatin profoundly 
diminished the tumor volume in the NTC group, while 
it exerted no observable effects in the RhoE knockdown 
group (Supplementary Figure 3B). It should be noted that 
both knockdown of RhoE and overexpression of ROCK2 
suppressed HCC growth. This was in line with the results 
from other groups [18], suggesting activation of Rho/
ROCK signaling has growth suppressive effect in HCC. 
This effect may be due to the interaction between the 
adhesive contexts in the local microenvironment and the 
cytoskeletal tension brought by Rho/ROCK activation [19].
In the hope that ROCK inhibitor may serve as a 
putative chemo-sensitizing therapy in treating HCC, 
we examined the effect of Y27632 in combination with 
cisplatin. Subcutaneous injection model was performed 
as mentioned above using parental BEL-7402 cells. The 
mice were divided into four groups and received i) PBS, 
ii) Y27632, iii) cisplatin, and iv) cisplatin+Y27632, 
respectively. A lower concentration of cisplatin (3 mg/kg) 
was used in this experiment comparing to the dose 
(4 mg/kg) used in Figure 3A in order to clearly show the 
effect of Y27632 on sensitizing HCC cells to cisplatin. 
Treatment of Y27632 alone showed no difference in 
tumor growth rate compared to PBS. Cisplatin slightly 
suppressed the tumor growth while the combined 
treatment of cisplatin and Y27632 had remarkable 
synergistic effect of suppressing tumor growth (Figure 3B). 
In addition, we also tested the effect of the combined 
treatment of cisplatin and Y27632 in an orthotopic model 
using parental MHCC-97L cells. Only cisplatin+Y27632 
could significantly inhibit tumor growth in the orthotopic 
model, although the effect was not as drastic as in the 
subcutaneous model (Supplementary Figure 3C). It should 
be noted that in previous report, Y27632 was given into the 
peritoneal cavity with micro-osmotic pumps, which then 
ensured a more stable dose and hence persistent effect [20]. 
Nonetheless, collectively, these findings indicate that ROCK 
inhibitor exhibits chemo-sensitizing effects in vivo in HCC.
enhanced rocK2 activity promotes the 
activation of JAK2/stAt3
In order to elucidate the underlying molecular 
mechanism of how RhoE/ROCK2 might regulate HCC 
chemoresistance, we screened a number of pro-survival 
signaling pathways and identified JAK2/STAT3 as a 
candidate. With Western blotting, we found that RhoE 
knockdown by siRNA in BEL-7402 and SMMC-7721 
enhanced the phosphorylation of both JAK2 and STAT3 
(Figure 4A). Consistently, addition of Y27632 repressed 
the phosphorylation of JAK2 and STAT3 (Figure 4B). 
Furthermore, phosphorylation of STAT3 was also 
upregulated in ROCK2-overexpressing BEL-7402 cells 
when compared to the vector control (Supplementary 
Figure 4).
STAT3 is a transcription factor which regulates the 
transcription of pro-survival genes such as survivin, c-myc 
and cyclin D [9]. To validate that the transcription activity 
of STAT3 was upregulated by ROCK2, we constructed a 
vector expressing firefly luciferase under the control of 6× 
STAT3 binding elements. Using this construct, we showed 
that both ROCK inhibitor and knockdown of ROCK2 by 
siRNA decreased the STAT3-mediated transcription of 
firefly luciferase (Figure 4C). Using Western blotting, 
we also observed that one of the target genes of STAT3, 
c-myc, was downregulated after addition of Y27632 
to HCC cells (Figure 4D). Furthermore, we stained for 
p-STAT3 in the tumors harvested from the subcutaneous 
injection model in Figure 3B. We found strong nuclear 
stain of p-STAT3 in both the PBS and cisplatin-alone 
groups. In contrast, the p-STAT3 level was markedly 
abrogated in both Y27632-alone and cisplatin+Y27632 
groups. In particular, the p-STAT3 stain was nearly 
totally abolished in cisplatin+Y27632 group (Figure 4E). 
The data suggest that RhoE/ROCK2 modulates 
chemoresistance in HCC via the JAK2/STAT3 pathway. 
Indeed, addition of JAK2 inhibitor AG490 to BEL-7402 
cells repressed phosphorylation of STAT3 and sensitized 
the cells to cisplatin treatment in a dose-dependent manner 
(Supplementary Figure 5A) and addition of AG490 was 
able to rescue the enhanced chemoresistance in ROCK2 
overexpressing BEL-7402 cells (Supplementary Figure 5B). 
rhoe/rocK2 regulates the expression of Il-6 
and Il-6 receptor
To explore the mechanism how JAK2/STAT3 were 
activated by ROCK2, we used Y27632 and then examined 
the expression of the IL-6 receptor complex and IL-6. 
After treating with Y27632 for 24 hours, the mRNA 
expression levels of IL-6R, gp130 and IL-6 were all 
significantly reduced in SMMC-7721 and BEL-7402 cells 
(Figure 5A and 5B). Reciprocally, knockdown of RhoE 
enhanced the IL-6 mRNA expression when compared with 
the corresponding NTCs (Figure 5C). To further confirm 
that the alteration in ROCK signaling indeed affected the 
secretion of functional IL-6, we used IL-6-specific ELISA 
assay to detect IL-6 level in the HCC-cell-conditioned 
media. We found that after incubating SMMC-7721 
and BEL-7402 cells with Y27632 for 24 hours, level of 
IL-6 in each of the conditioned media was dramatically 
reduced as compared to the mock controls (Figure 5D). 
Consistently, the IL-6 level in the conditioned medium 
of the ROCK2-overexpressing cells showed significant 
increases as compared with that of the vector control cells 
(Supplementary Figure 6). Altogether these data strongly 
indicate that RhoE/ROCK2 regulate the expression levels 
of IL-6 and IL-6 receptor.
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rho/rocK signaling targets Il-6/JAK2/stAt3 
through NF-κB
Although we demonstrated that Rho/ROCK 
signaling regulated the chemoresistance in HCC through 
IL-6/JAK2/STAT3, the direct phosphorylation target of 
ROCK2 remained unrevealed. Recent study has reported 
that IKKβ is a direct phosphorylation target of ROCK [21]. 
Since IL-6 is a well-documented target of NF-κB [22], 
this suggests that Rho/ROCK may induce IL-6/JAK2/
STAT3 pathway through direct phosphorylation of IKKβ 
and activation of NF-κB. To elucidate this possibility, we 
assessed the p-IκBα and p-IKKβ levels with Western blot 
analysis. We observed significant reduction of p-IκBα and 
p-IKKβ after Y27632 treatment in both SMMC-7721 and 
BEL-7402 cells (Figure 6A and 6B). We also compared 
transcriptional activation activity of NF-κB between 
ROCK-inhibited cells and their corresponding controls 
by firefly luciferase reporter assay. Both knockdown of 
ROCK2 by siRNA and treatment with Y27632 suppressed 
the firefly luciferase signal indicating repressed activity 
of NF-κB (Figure 6C). To further confirm our result, we 
also examined the activity of NF-κB in our ROCK2-
overexpressing cells using firefly luciferase reporter 
assay. Both ROCK2-overexpressing clones displayed 
enhanced firefly luciferase signal as compared with to 
their corresponding vector controls (Supplementary 
Figure 7). To demonstrate that IL-6 was also a direct 
Figure 3: rho/rocK activity modulates Hcc chemoresistance in vivo. (A and b) Xenograft tumor growth derived from 
subcutaneously injected HCC cells in nude mice. Tumors were first allowed to grow to about 100 mm3 in size and then different treatments 
were given to the mice as described below. (A) RhoE knockdown BEL-7402 cells and NTC were used. Mice were given either 4 mg/kg 
cisplatin or PBS through intraperitoneal injection once every 3 days. Cisplatin only slowed down the growth of NTC tumors but not that of 
RhoE knockdown tumors. (B) Parental BEL-7402 cells were used. Mice were given i) PBS, ii) 4 mg/kg Y27632, iii) 3 mg/kg cisplatin, and iv) 
3 mg/kg cisplatin + 4 mg/kg Y27632, respectively, through intraperitoneal injection once every 3 days. Combined treatment of cisplatin and 
Y27632 had synergistic effect in suppressing HCC tumor growth than cisplatin alone. Representative result from 3 experiments is shown. 
P-value was calculated using non-linear regression.
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Figure 4: Inhibition of rocK repressed the activity of JAK2 and stAt3. (A) Knockdown of RhoE by siRNA induced 
phosphorylation of both JAK2 and STAT3 in BEL-7402 and SMMC-7721 cells. (b) Treatment with Y27632 for 24 hours inhibited the 
phosphorylation of JAK2 and STAT3 in BEL-7402 and SMMC-7721 cells. (c) Schematic diagram showing the construct which expressed 
firefly luciferase under the control of STAT3-binding elements. Both Y27632 and ROCK2 knockdown by siRNA reduced the luciferase 
activity in BEL-7402 cells. SV40-driven expression of Renilla luciferase was used as normalization control. (d) Treatment with Y27632 for 
24 hours decreased the protein level of c-myc, a transcriptional target of STAT3, in BEL-7402 and SMMC-7721 cells. (e) Representative 
IHC staining of p-STAT3 (Y705) in xenograft tumors harvested from subcutaneous tumor injection model (Figure 3B). Y27632 remarkably 
diminished the p-STAT3 (Y705) signals; the p-STAT3 stain was nearly totally abolished in the combined Y27632 and cisplatin treatment 
group. Original magnification, ×20; scale bars: 200 μm. 10 μM Y27632 was used. In all panels, 3 experiments are represented. P-value was 
calculated using Student’s t test.
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Figure 5: rho/rocK signaling regulates expressions of Il-6 receptor and Il-6. (A and b) Real-time qPCR was used to 
measure the mRNA levels of (A) IL-6R and gp130, and (B) IL-6 in mock and Y7632-treated BEL-7402 and SMMC-7721 cells. Y27632-
treated cells had reduced mRNA expression of IL-6R, gp130 and IL-6. (c) Knockdown of RhoE significantly augmented the mRNA 
expression of IL-6 in BEL-7402 and SMMC-7721 cells as compared to the corresponding NTCs. (d) ELISA assay was used to assess IL-6 
secretion to the cultured medium by BEL-7402 and SMMC-7721 cells. Inhibition of ROCK by 24-hour treatment of Y27632 markedly 
repressed IL-6 secretion. 10 μM Y27632 was used. In all panels, 3 experiments are represented. P-value was calculated using Student’s t test.
Oncotarget41453www.impactjournals.com/oncotarget
downstream target of NF-κB in HCC cells, we treated 
SMMC-7721 and BEL-7402 with NF-κB inhibitor BAY 
11-7082 for a short period of time (4 hours). The result 
showed that inhibition of NF-κB for 4 hours already 
significantly reduced the mRNA level of IL-6 and in a 
dose-dependent manner (Figure 6D). On the other hand, 
addition of BAY 11-7082 for 4 hours had no observable 
effects on the mRNA expression level of either IL-6R or 
gp130 (Supplementary Figure 8A). Treatment of Y27632 
decreased pIKKα/β at around 6 hours as compared with 
the untreated cells. On the other hand, the pJAK2 level 
was lower in the Y27632-treated cells after 12 hours and 
pSTAT3 was suppressed in Y27632-treated cells after 24 
hours (Supplementary Figure 9). This indicates that the 
effect of NF-κB on IL-6 signaling is mainly due to the 
change in the expression of the ligand without affecting 
the expression of the receptor complex. These findings 
support that Rho/ROCK signaling upregulates the activity 
of IL-6/JAK2/STAT3 pathway via phosphorylation of 
IKKβ and activation of NF-κB.
ROCK2 expression correlates with NF-κB and 
Il-6 activations in human Hccs
We then speculated that the relationship 
between ROCK signaling and activation of IL-6 and 
NF-κB was also of clinical significance. To test this 
hypothesis, we examined the mRNA levels of both 
ROCK2 and IL-6 in a cohort of 35 human HCC tissue 
samples by qPCR. We demonstrated that the IL-6 
expression positively and significantly correlated 
with the ROCK2 expression in our sample cohort 
(Spearman’s r = 0.4779, P = 0.004) (Figure 7A). 
Furthermore, we also utilized the data of HCC patients 
from the TCGA database. According to the TCGA data, 
ROCK2 expression positively and significantly correlated 
with those of IL6R, gp130, c-myc and VEGF in HCC 
patients (Figure 7B). This suggests that higher ROCK2 
expression levels correlate with activation of IL-6 and NF-
κB signaling in HCC patients.
dIscussIon
Our findings in this study have revealed that RhoE/
ROCK2 signaling is one of the important regulators 
contributing to the high chemoresistance of HCC. In 
the model illustrated in Figure 8, we propose that both 
downregulation of RhoE and upregulation of ROCK2 
lead to the augmentation of the ROCK2 activity. As a 
consequence, ROCK2 promotes the phosphorylation 
of IKKβ and activation of NF-κB, which then turns on 
the transcription of IL-6. IL-6 acts through an autocrine 
cycle, resulting in hyper-activation of STAT3. This in turn 
leads to the transcriptional activation of STAT3-specific 
target genes and promotion of cell survival. Our in vivo 
tumor growth study strongly suggests that inhibitors 
targeting ROCK2 have great potential to serve as a chemo-
sensitizing therapy in HCC. In particular, the dramatic 
effect of combined Y27632 and cisplatin in inhibiting 
tumor growth over that of cisplatin alone in nude mice 
model indicates that the activation of ROCK2 may be 
crucial for maintaining the chemoresistance of HCC cells. 
Importantly, there was a positive association between 
the expression levels of ROCK2 and activation of IL-6 
and NF-κB in HCC samples from patients. This further 
supports the clinical relevance of Rho/ROCK signaling 
in regulating chemoresistance, as IL-6 has been well 
documented to be a pro-survival cytokine in cancers [23]. 
Since ROCK has two isoforms, it is important to 
identify which one is specific and required for promoting 
chemodrug-resistance, in order to develop more specific 
inhibitors to improve targeting efficacy and reduce 
potential cytotoxicity. To our knowledge, although several 
studies have reported that inhibition of both ROCK1 and 
ROCK2 by pan-ROCK inhibitors could induce apoptosis 
in cancer cells [7, 15], the isoform-specific effect of 
ROCK1 and ROCK2 has not yet been explored. This 
is partially due to the reason that the two kinases share 
high homology in amino acid sequence (65%) and even 
higher homology in their kinase domains (95%). Despite 
the high similarity between the two isoforms, there is 
evidence suggesting they are not functionally redundant 
[13, 24]. By knocking down each isoform individually, we 
clearly demonstrated that only ROCK2 was responsible 
for promoting chemoresistance in HCC. We believed that 
two isoforms contribute differently in regulating apoptosis 
in HCC cells. It was demonstrated that inhibition of 
ROCK1 activation only abolish the fragmentation of 
apoptotic cells but does not halt the apoptotic process 
itself [25]. Based on our data, it is likely that in HCC 
only ROCK2 can protect the cells from entering apoptosis 
while ROCK1 only participates in late apoptotic events 
and has no effect on the initiation of apoptosis. It will 
be of interest to test whether ROCK2-specific inhibitors 
such as KD025 [26] serve as a better anti-metastatic and 
chemo-sensitizing therapy over the pan-ROCK inhibitors. 
Our team had previously shown that MHCC-97L cells 
expressed a lower level of miR-139, which is a ROCK2 
expression inhibitor, than BEL-7402 and SMMC-7721 
cells. Therefore it is not surprising to see that the chemo-
sensitization effect of Y27632 was weaker in MHCC-97L 
cells than in BEL-7402 and SMMC-7721 cells. Hence a 
higher dose of Y27632 may be required in patients with 
higher endogenous ROCK2 activity.
Active RhoA has been reported to activate STAT3 by 
phosphorylation at both Y705 and S727 in HEK cells [11]. 
Nevertheless, the exact molecular mechanism of how Rho 
GTPase activates STAT3 signaling is likely to be cell-type 
dependent and remains unknown in HCC. Sanz-Moreno 
et al demonstrated that in melanoma cells and the cancer-
associated fibroblasts (CAFs), addition of pan-ROCK 
inhibitor H-1152 could suppress STAT3 phosphorylation 
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Figure 6: Rho/ROCK promotes IL-6 transcription via activation of IKKβ/NF-κB. (A) Proteasome inhibitor MG132 was 
added to inhibit the degradation of p-IκBα. p-IκBα was reduced by 24-hour treatment of 10 μM Y27632 in BEL-7402 and SMMC-7721 
cells. (b) BEL-7402 and SMMC-7721 cells were treated with indicated concentrations of Y27632 for 3 hours. Phosphorylation of IKKβ was 
suppressed by Y27632 treatment. (c) Inhibition of ROCK by Y27632 and ROCK2 knockdown both repressed NF-κB-driven transcription 
of firefly luciferase. SV40-driven expression of Renilla luciferase was used as normalization control. (d) BEL-7402 and SMMC-7721 cells 
were treated with the indicated concentration of NF-κB inhibitor, BAY11-7082, for 4 hours. mRNA expression level of IL-6 was decreased 
by BAY11-7082 in a dose-dependent manner. In all panels, 3 experiments are represented. P-value was calculated using Student’s t test.
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Figure 7: Clinical correlation of ROCK2 and activation of NF-κB and IL-6 signaling in HCC. (A) The mRNA levels 
of ROCK2 and IL-6 in clinical HCC samples (n = 35) were measured by qPCR. HPRT was used as the endogenous control. ROCK2 
expression was found to positively correlate with IL-6 expression with Spearman’s r = 0.4779 (b) The mRNA expression levels of ROCK2 
positively correlated with those of IL6R, gp130, c-myc and VEGF by Spearman’s rank correlation in HCC patients’ data from TCGA.
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through repression of JAK [27]. In another report, Huang 
et al also identified JAK2 to be a direct target of ROCK1 
in hypothalamic cells [28]. In these two reports, JAK 
phosphorylation was immediately abolished following 
inhibition of ROCK within 30 minutes, indicating 
that Rho/ROCK controls STAT3 signaling via direct 
manipulation of p-JAK levels. In contrast, in our study, 
the effect of Y27632 on suppressing the phosphorylation 
of STAT3 in HCC cells was only observed after at least 
24 hours of incubation. Therefore JAK is unlikely to be the 
direct downstream target of ROCK in HCC and the effect 
of STAT3 activation following ROCK activation may be 
mediated by the increase in expression of autocrine IL-6, 
as in the case of Rac1-regulated STAT3 activation [29].
NF-κB is one of the most well-studied regulators 
of IL-6 expression [30]. Very recently, ROCK has been 
reported to directly phosphorylate IKKβ [21]. It is 
reasonable to hypothesize that ROCK mediates IL-6/
JAK2/STAT3 activation through direct regulation of IKK 
phosphorylation. In support of this, our result showed 
that transient inhibition of ROCK for 3 hours could 
already reduce phosphorylation of IKKβ in HCC cells. 
This suggests that the NF-κB pathway is likely the direct 
effector of Rho/ROCK signaling. NF-κB activation leads 
to accumulation of IL-6 which in turn activates JAK2 
and STAT3. Enhanced expression of IL-6R and gp130 
should be a subsequent event of STAT3 activation since 
they are putative transcription targets of STAT3 [31, 32]. 
The activated STAT3 may then induce more transcription 
of IL-6, which forms a positive feedback loop and confer 
hyper-chemoresistance to HCC cells [33]. 
Currently, no ROCK inhibitors are approved for use 
to treat human cancers. Nevertheless, there is growing 
evidence that ROCK inhibition suppresses both cancer 
progression and metastasis in murine models [20, 34]. 
In this study, we have further discovered that ROCK2 
activation is necessary for maintaining the highly 
chemoresistant nature of HCC. It is conceivable that 
ROCK2 is an attractive therapeutic target in HCC, since 
ROCK2 inhibitors may serve as both anti-metastasis and 
chemo-sensitizing agents in HCC patients.
Figure 8: A schematic model of rho/rocK promoting chemoresistance in Hcc.
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MAterIAls And MetHods
cell lines, reagents and plasmids
Human HCC cell lines, SMMC-7721 and 
BEL-7402 and immortalized normal liver cell line LO2 
were obtained from Shanghai Institute of Cell Biology, 
Chinese Academy of Sciences. MHCC-97L was a gift from 
Fudan University (Dr. ZY Tang) of Shanghai. BEL-7402 
and MHCC-97L cells are hepatitis B surface antigen 
(HBsAg) positive. SMMC-7721, BEL-7402, MHCC-97L 
and LO2 were maintained in Dulbecco’s modified Eagle’s 
medium with high glucose (Gibco-BRL, Carlsbad) 
supplemented with 10% fetal bovine serum. Y27632, 
MG132, AG490 and BAY11-7082 were purchased from 
Selleckchem (Houston). Cisplatin and doxorubicin were 
purchased from Pharmachemie BV (Haarlem). The plasmids 
for STAT3 and NFκB luciferase reporter assays were 
constructed by cloning STAT3 and NFκB binding elements 
into pGL3(Promega, Wisconsin) using NheI and BgIII.
real-time quantitative Pcr (q-Pcr)
RNA was extracted with TRIzol reagent (Invitrogen, 
Carlsbad). cDNA was synthesized with 1 μg of total RNA 
using the Gold RNA PCR core kit (GeneAmp, Carlsbad) 
and random primers. Quantitative PCR (q-PCR) was 
performed in triplicate, using the SYBR® Green Real-Time 
PCR Master Mixes and the Applied Biosystems 7900HT 
Fast Real-Time PCR system (Applied Biosystems, 
Carlsbad) according to manufacturer’s instructions.
drug response assay
3 × 106 cells were seeded in 35-mm culture plates 
24 hours prior to experiment. Cells were replenished with 
2 mL fresh culture medium containing 20 µg/mL cisplatin 
or 2 µg/mL doxorubicin and incubated at 37oC for 48 hours. 
After 48 hours both dead flowing cells and live cells were 
collected, resuspended in 1 mL PBS and were stained with 
Trypan Blue. Live cells and dead cells were counted by 
hematocytometer. 
Annexin V apoptosis assay
3 × 106 cells were seeded in 35-mm culture plates 
24 hours prior to the experiment. Cells were replenished 
with 2 mL fresh culture medium containing 20 µg/mL 
cisplatin for 24 hours. After 24 hours, both dead flowing 
cells and live cells were trypsinized and collected. 
Annexin V Apoptosis Detection Kit I (BD Biosciences, 
San Jose) was used according to manufacturer’s protocol. 
The stained cells were analyzed by BD FACSCantoII 
Analyzer (BD Biosciences).
Xenograft assay
6-week-old BALB/c-nu/nu athymic male nude mice 
were used. All animals were provided by the Laboratory 
Animal Unit of the University of Hong Kong. 2 × 106 cells 
resuspended in 100 μL PBS were injected subcutaneously 
into both sides of the mice’s back. For subcutaneous assay, 
tumor was allowed to grow until it reached 100 mm3. For 
orthotopic assay, tumor was allowed to grow for 1 week. 
After that, cisplatin and/or Y27632 were administered every 
3 days to the mice via intraperitoneal injection. The tumor 
dimensions were also measured every 3 days. The volume 
of the tumor was estimated with the following formula: 
Tumor volume = shortest dimension × longest dimension2
luciferase assay
5 × 104 cells were seeded in 24-well plate overnight. 
Renilla luciferase was used as the normalization control. 
Cells were transfected with 1 μg of total DNA of 1 (Renilla 
luciferase plasmid):100 (firefly luciferase reporter plasmid) 
using Lipofectamine 2000 (Invitrogen). Each sample was 
repeated in triplicate. 48 hours after transfection, luciferase 
assay was performed using the Dual-luciferase Reporter 
Assay System (Promega) according to the manufacturer’s 
protocol. The luminescence was measured by Infinite 200 
(Tecan, Männedorf).
tcGA datasets
We collected transcriptomic data of HCC patients 
from The Cancer Genome Atlas (TCGA). Gene expression 
data (RNA-seq) were downloaded from cBioPortal [35]. 
Co-expression analysis was performed using Prism5.
statistics
Results are reported as mean ± SEM. Significance 
was tested by 2-tailed Student’s t test. Mann–Whitney 
U test was used to compare luciferase signal in lung 
in xenograft mdoel. Cell proliferation rate and tumor 
growth rate were tested by non-linear regression test. 
Gene correlation was determined by Pearson correlation. 
A P value of less than 0.05 was considered significant.
study approval
Use of human HCC samples was approved by the 
Institutional Review Board of the University of Hong 
Kong/Hospital Authority Hong Kong West Cluster. 
Written informed consent for participation in the study 
was obtained from all participants. The procedures for 
collecting and using tissues from the patients were in 
accordance with the ethical standards established in the 
Declaration of Helsinki. All animal experiments were 
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approved by the Committee on the Use of Live Animals 
in Teaching and Research, the University of Hong Kong 
and performed according to the Animals (Control of 
Experiments) Ordinance (Hong Kong) and the Institute’s 
guidance on animal experimentation.
Additional methods can be found in Supplementary 
Methods.
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